Back to top
more

Virtus Biotech Clinical Trials ETF: (BBC)

(Delayed Data from NYSE) As of Nov 20, 2026 03:59 PM ET

$38.17 USD

38.17
53,413

-1.60 (-4.02%)

Volume: 53,413

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $38.55 +0.38 (1.00 %) 7:58 PM ET

Zacks News

Sanghamitra Saha headshot

5 Best Areas of Q3 of 2022 & Their Top ETFs

These ETF areas won in the third quarter of 2022.

Sweta Killa headshot

Biotech Wins Last Week: 5 Best ETFs

The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.

Sanghamitra Saha headshot

Stocks' Best Month Since 2020: Top ETF Areas of July

Wall Street logged the best month since November 2020 in July. These are the winning ETFs.

Sanghamitra Saha headshot

3 ETFs Braving Inflationary Fears in Past Three Months

These ETFs have braved the inflationary fears in the past three months and topped the S&P 500.

Zacks Equity Research

The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO

BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.

Sweta Killa headshot

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Sanghamitra Saha headshot

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Sweta Killa headshot

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.

Sweta Killa headshot

4 Sector ETFs That Survived Market Turmoil in June

June has proved to be a brutal month for the stock market. The combination of factors such as decades-high inflation, the Russia-Ukraine conflict and Fed¿¿¿s aggressive tightening policy are weighing heavily on investors' sentiment.

Sanghamitra Saha headshot

ETFs Winners of S&P 500's Second Best Week in 2022

The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.